End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
24.22 CNY | +3.46% |
|
-4.65% | -30.52% |
Apr. 10 | China stocks down pressured by real estate; HK shares up | RE |
Apr. 09 | Beijing Kawin Technology Share-Holding Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With a 2024 P/E ratio at 28.03 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.52% | 539M | - | ||
+16.61% | 121B | B+ | ||
+17.75% | 110B | B+ | ||
+17.23% | 25.98B | B | ||
-24.11% | 19.27B | B+ | ||
-18.56% | 15.99B | A- | ||
-18.47% | 15.66B | B | ||
-47.75% | 14.5B | A- | ||
+57.35% | 14.47B | C+ | ||
+5.62% | 13.91B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688687 Stock
- Ratings Beijing Kawin Technology Share-Holding Co., Ltd.